Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS, INC. | 2025-12-02 08:29:34 | 22.55 | -0.14 | -0.62 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPRX | 0001369568 | CATALYST PHARMACEUTICALS, INC. | US14888U1016 | 5299004O0R5XXLA5H544 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 355 ALHAMBRA CIRCLE | CORAL GABLES | FL | 33134 | UNITED STATES | US | (305) 529-2522 | 355 ALHAMBRA CIRCLE, CORAL GABLES, FL, 33134 | 355 ALHAMBRA CIRCLE, CORAL GABLES, FL, 33134 | CATALYST PHARMACEUTICALS, INC. | Biotechnology | — | Patrick J. McEnany (chairman Richard Daly | 176 | http://www.catalystpharma.com/ | 1,720,853,867 | 123,264,583 | 122,912,387 | Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019. | 2025-11-27 16:20:49 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 1,720,853,867 | 379,549,165 | 28.297 | 121,449,655 | 3,586,397 | 3.0428 |
| 2023 | 1,341,304,702 | 675,713,754 | 101.5209 | 117,863,258 | 11,886,299 | 11.2159 |
| 2022 | 665,590,948 | -550,915,930,052 | -99.8793 | 105,976,959 | 3,196,808 | 3.1103 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 181 |
| 2023 | 167 |
| 2022 | 82 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 491,734,000 | 398,204,000 | 214,203,000 |
| Cost Of Revenue | 68,845,000 | 51,967,000 | 34,393,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 12,648,000 | 93,150,000 | 19,789,000 |
| General And Administrative Expenses | 58,994,000 | 133,710,000 | 58,183,000 |
| Operating Expenses | 190,388,000 | — | — |
| Operating Income | 195,124,000 | 86,812,000 | 101,838,000 |
| Net Income | 163,889,000 | 71,410,000 | 83,079,000 |
| Earnings Per Share Basic | 1.38 | 0.67 | 0.8 |
| Earnings Per Share Diluted | 1.31 | 0.63 | 0.75 |
| Weighted Average Shares Outstanding Basic | 118,457,673 | 106,279,736 | 103,374,606 |
| Weighted Average Shares Outstanding Diluted | 124,943,603 | 113,753,154 | 111,375,631 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 517,553,000 | 137,636,000 | 298,395,000 |
| Marketable Securities Current | — | 0 | 0 |
| Accounts Receivable | 65,476,000 | 53,514,000 | 10,439,000 |
| Inventories | 19,541,000 | 15,644,000 | 6,805,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 623,609,000 | 219,329,000 | 320,797,000 |
| Marketable Securities Non Current | — | — | 0 |
| Property Plant And Equipment | 1,354,000 | 1,195,000 | 847,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 227,802,000 | 250,785,000 | 54,833,000 |
| Total Assets | 851,411,000 | 470,114,000 | 375,630,000 |
| Accounts Payable | 16,593,000 | 14,795,000 | 3,975,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 104,085,000 | 61,268,000 | 53,613,000 |
| Total Liabilities Current | 120,678,000 | 76,063,000 | 57,588,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 315,000 | 2,982,000 | 14,064,000 |
| Total Liabilities Non Current | 3,101,000 | 6,170,000 | 17,621,000 |
| Total Liabilities | 123,779,000 | 82,233,000 | 75,209,000 |
| Common Stock | 121,000 | 107,000 | 105,000 |
| Retained Earnings | 285,161,000 | 121,272,000 | 49,862,000 |
| Accumulated Other Comprehensive Income | 64,000 | 14,000 | 24,000 |
| Total Shareholders Equity | 727,632,000 | 387,881,000 | 300,421,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 397,000 | 316,000 | 141,000 |
| Share Based Compensation Expense | 22,251,000 | 14,250,000 | 7,907,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 11,962,000 | 43,075,000 | 3,820,000 |
| Change In Inventories | 3,897,000 | 4,739,000 | -1,065,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 1,798,000 | 10,820,000 | 1,207,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 239,808,000 | 143,600,000 | 116,047,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | 0 | — | 19,238,000 |
| Acquisition Of Property Plant And Equipment | 556,000 | 231,000 | 29,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -556,000 | -293,502,000 | 9,209,000 |
| Tax Withholding For Share Based Compensation | 668,000 | 982,000 | 230,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 141,000,000 | — | — |
| Repurchase Of Common Stock | 0 | — | 6,907,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 140,665,000 | -10,857,000 | 1,694,000 |
| Change In Cash | 379,917,000 | -160,759,000 | 126,950,000 |
| Cash At End Of Period | 517,553,000 | 137,636,000 | 298,395,000 |
| Income Taxes Paid | 68,451,000 | 50,458,000 | 7,667,000 |
| Interest Paid | 1,395,000 | 705,000 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 1.38 | 0.67 | 0.8 |
| Price To Earnings Ratio | 15.1232 | 25.0896 | 23.25 |
| Earnings Growth Rate | 105.9701 | -16.25 | 110.5263 |
| Price Earnings To Growth Ratio | 0.1427 | -1.544 | 0.2104 |
| Book Value Per Share | 6.1425 | 3.6496 | 2.9061 |
| Price To Book Ratio | 3.3976 | 4.606 | 6.4002 |
| Ebitda | 232,737,000 | 122,184,000 | 90,887,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 556,000 | 664,000 | 29,000 |
| Free Cash Flow | 239,252,000 | 142,936,000 | 116,018,000 |
| Return On Equity | 0.2252 | 0.1841 | 0.2765 |
| One Year Beta | 1.171 | 0.9285 | 1.1613 |
| Three Year Beta | 1.0983 | 1.0864 | 1.3364 |
| Five Year Beta | 1.2894 | 1.3053 | 1.3058 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Del Carmen Jeffrey | Chief Commercial Officer | 2025-11-26 | 10,983 | A | 14,945 |
| Del Carmen Jeffrey | Chief Commercial Officer | 2025-11-26 | 10,983 | D | 3,962 |
| Del Carmen Jeffrey | Chief Commercial Officer | 2025-11-26 | 10,983 | A | 1,053,552 |
| Del Carmen Jeffrey | Chief Commercial Officer | 2025-11-21 | 5,603 | A | 5,603 |
| Del Carmen Jeffrey | Chief Commercial Officer | 2025-11-21 | 1,641 | D | 3,962 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cambria Investment Management, L.P. | 2025-09-30 | 427,825 | 21,717 | 19.7 |
| Strategic Advocates LLC | 2025-09-30 | 3,566 | 181 | 19.7017 |
| JPMORGAN CHASE & CO | 2025-09-30 | 7,462,497 | 378,807 | 19.7 |
| CIBC Private Wealth Group LLC | 2025-09-30 | 108,902 | 5,528 | 19.7001 |
| Bell Investment Advisors, Inc | 2025-09-30 | 2,640 | 134 | 19.7015 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYWCX | 2,163 | 42,611.1 | 0.8945 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class A | RYSGX | 2,163 | 42,611.1 | 0.8945 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class H | RYWAX | 2,163 | 42,611.1 | 0.8945 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYCMX | 161 | 3,171.7 | 0.0475 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class A | RYAKX | 161 | 3,171.7 | 0.0475 |